Well I'm no expert in MCTT (Medical Clinical Trial Timelines) but Im guessing you could minus 3 months from Prep time (trial design, Pre 3 meetings with FDA etc), and at least another 3 months for recruitment and then a full 1 year min for the trial and then 6 months to review results, whats that, a total of say 2 years saving. Thats the whole idea, its such a critically required drug, its safe and there is NOTHING else that can be currently used, its filling an unmet need.
SO instead of it being 1.5 years (Phase 2) plus 2 years min (Phase 3), we might get away with just 2 years all up before commercialisation. This is also postulated by 51Capital who suggested something like a 2021 release for PPS to combat MPS.
Long time frames sure, but hey, 2 years is better than 4 plus.
Do your own research, these are just my opinions.
- Forums
- ASX - By Stock
- PAR
- Ann: Appendix 3B
PAR
paradigm biopharmaceuticals limited..
Add to My Watchlist
0.00%
!
33.0¢

Ann: Appendix 3B, page-6
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
33.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $131.1M |
Open | High | Low | Value | Volume |
32.5¢ | 35.0¢ | 31.8¢ | $341.6K | 1.052M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 30207 | 33.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
34.0¢ | 60000 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 30207 | 0.330 |
1 | 15000 | 0.325 |
7 | 223988 | 0.320 |
5 | 23598 | 0.315 |
3 | 43229 | 0.310 |
Price($) | Vol. | No. |
---|---|---|
0.340 | 60000 | 2 |
0.350 | 7689 | 2 |
0.355 | 26886 | 3 |
0.360 | 100000 | 1 |
0.365 | 23790 | 3 |
Last trade - 16.10pm 07/08/2025 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |